LIXTE BIOTECHNOLOGY HOLDINGS, INC. 8-K

What Happened Lixte Biotechnology Holdings, Inc. filed a Form 8-K reporting that on March 18, 2026 the company and CEO Geordan Pursglove entered into an Amendment to his Employment Agreement. The Amendment increases his annual base salary from $240,000 to $360,000, effective January 1, 2026. The change follows the original Employment Agreement dated June 16, 2025 and was approved by the company’s Compensation Committee and Board of Directors.

Key Details

• Effective date: January 1, 2026 (salary change applied retroactively to start of year)
• Salary change: from $240,000 to $360,000 annually — an increase of $120,000 (50%)
• Approval: Amendment approved by the company’s Compensation Committee and Board of Directors
• Filing: Amendment is included as Exhibit 10.1 to the Form 8-K filed March 20, 2026

Why It Matters This amendment increases the company’s recurring cash compensation expense for its CEO by $120,000 per year, which is a quantifiable change to operating costs. Approval by the Compensation Committee and Board indicates the raise was reviewed at the governance level. There are no other officer departures or role changes reported in this filing. Investors may note the compensation change for modeling near‑term operating expenses and assessing executive retention incentives.